Hybrid extracorporeal liver support is an option to assist liver transplantation therapy. An overview on liver cell bioreactors is given and our own development is described. Furthermore, the prospects of the utilization of human liver cells from discarded transplantation organs due to steatosis, cirrhosis, or traumatic injury, and liver progenitor cells are discussed. Our Modular Extracorporeal Liver Support (MELS) concept proposes an integrative approach for the treatment of hepatic failure with appropriate extracorporeal therapy units, tailored to suit the actual clinical needs of each patient. The CellModule is a specific bioreactor (charged actually with primary human liver cells, harvested from human donor livers found to be unsuitable for transplantation). The DetoxModule enables albumin dialysis for the removal of albumin-bound toxins, reducing the biochemical burden of the liver cells and replacing the bile excretion of hepatocytes in the bioreactor. A Dialysis Module for continuous veno-venous hemofiltration can be added to the system if required in hepato-renal syndrome.
PROSPECTS OF THE USE OF HEPATIC CELLS
in ALF under conservative treatment ranges from 79% (amanita intoxication) to 10% (cryptogeneic genesis).
FOR EXTRACORPOREAL LIVER SUPPORT
Introduction of liver transplantation (LTx) as therapeutic option reduced mortality to 20-40% (10) . Patients with liver disease, fulminant and chronic, can progressively worsen until they require orthotopic With the continued, growing disparity between the numbers of organ donations and patients waiting for liver transplantation (OLT), which is the only recognized effective treatment (67) . The American Liver liver transplantation, efforts have been made to design extracorporeal methods to support or replace the failing Foundation estimates that 1 in 10 people have some form of liver disease and 26,000 people die each year liver. The frequent lack of donor livers for urgent transplantation in ALF highlights the need for a liver support from liver disease (3). In 2002, 16,929 people were listed for liver transplantation in the US, only 4778 catherapy until an organ becomes available. Moreover, patients with the capacity for liver recovery could be daveric donor liver transplants were made, and 1756 patients died while awaiting transplant (103). A medical bridged to regeneration and would not require transplantation at all. need for a treatment modality that can "bridge" patients to transplant or slow or reverse the progression of acute Progress in hepatocyte tissue engineering and in vitro maintenance of differentiated function of primary liver liver disease is clearly needed.
Acute liver failure (ALF) has a poor prognosis with cells has led to initial clinical pilot studies of extracorporeal support of patients in acute liver failure using bioremortality rates between 50% and 90% under conservative management (11) . Over the last 50 years, advances actors incorporating hepatocyte cultures (42, 69, 70, 77, 89, 104) . While encouraging, the nonsignificant results have been made in the understanding of the pathophysiology encompassing the clinical features of ALF: enfrom the only Phase III efficacy trial conducted to date (97) indicate that much further progress in understandcephalopathy, cerebral edema, hemorrhage, electrolyte and metabolic disturbances, renal failure, cardiovascular ing and controlling tissue engineering of complex hepatocyte bioreactors is required. One of the challenges is instability, and increased risk of infection. While cerebral edema is the most common cause of death, multiorthe creation of neovascularized tissue constructs at high cell density that avoid central necrosis and exhibit recagan failure and sepsis are also associated with significant mortality. Depending on etiology, the survival rate pitulation of the sinusoidal microvasculature of the liver. human liver tumor cell lines, the use of primary human human livers from discarded transplants. A cell mass of 400-600 g was obtained, enabling the clinical applicaliver cells seems to present a promising cell source.
Primary human liver cells, obtained from explanted tion of a liver lobe equivalent to a hybrid organ. Freshly isolated cell preparations contained about 10% of nonpaorgans found to be unsuitable for transplantation, are an interesting cell source as they are ethically acceptable renchymal cells, as estimated microscopically using size-selective criteria. Eighteen cell isolation procedures and are capable of performing human metabolism and regulation (102). According to Eurotransplant data, and (33.3%) failed because of unsatisfactory cell viability (<40%) and/or unsuccessful separation during the washthe data of the European and American organ procurement organizations, approximately 20-25% of all exing procedure, due to a higher grade of initial organ impairment. In 36 cases (66.7%), the isolation was perplanted livers are unsuitable for transplantation and therefore discarded. This number corresponds to the formed successfully. From these isolation procedures, 2.8-6.4 × 10 10 hepatocytes were cocultured in the biorenumber of patients with ALF requiring bridging to LTx (81). However, the initial viability of those cells is imactors (n = 36) with the nonparechymal cells of the same liver. Trypan blue viability of the cells prior to charging paired by preceding organ preservation and the isolation procedure.
the bioreactors was 55.0 ± 15.9%. After inoculation into bioreactors, metabolic activities of the cells in vitro were Our hypothesis is that, with appropriate logistics, after recovery from the preservation and isolation injury maintained over at least 3 weeks of culturing. in a four-compartment bioreactor, cells from these or-BIOREACTOR CULTURE OF LIVER gans could serve the demand for cell-based therapy, in-CELLS AND CLINICAL APPLICATIONS cluding extracorporeal liver support.
OF OUR OWN DEVELOPMENT In one of our studies, cells were isolated from 54 Maintenance of nondividing primary liver cells and their differentiated functions was demonstrated over a period of 2 months and may continue longer (29, 33, 35) . This bioreactor can accommodate a number of cells that would allow studies in extracorporeal liver support (27, 88, 90) . Animal studies showed encouraging results for the clinical use of the bioreactor (9, 21, 26, 28, 43, 52) .
Utilizing porcine cells, the device was used as a bridge to liver transplantation in a Phase I study with eight patients in ALF, coma stage III-IV (78) . To date the patient and organ survival rate is 100% with an observation period of 3 years (50, 89) .
A pilot study in Berlin, Germany, is using the device with primary human liver cells harvested from organs explanted for transplantation but subsequently discarded due to steatosis, cirrhosis, or mechanical injury (88) . These results demonstrate the feasibility of employing primary human liver cells in clinical applications with cells recover from organ preservation and cell isolation the cell source is crucial to enable further clinical studies. Stem cell research seeks to provide therapeutic soluinjury (42, 92) .
This novel technology enabled spontaneous cell reortions for this problem. ganization in the 600-g sample as well as human tissue LIVER PROGENITOR CELLS function over the period of several weeks (Fig. 3) . By AND BIOREACTOR CULTURES replacing the secondary capillary structure of the liver TO STUDY CELL SOURCES FOR lobuli with artificial hollow fibers for nutrition, mass ex-EXTRACORPOREAL LIVER SUPPORT change, and oxygenation (24), the cells spontaneously reformed the primary capillary structure of liver sinuStem cells-unspecialized cells that perpetuate themselves through self-renewal and generate specialized cells soids, thus supporting a larger cell mass at a higher density (91) . However, the limiting factor of liver support through differentiation (84)-may be the ideal cell source for cell-based therapies developed to treat debilistill remains the availability of primary human cells, as the present source is from discarded organs intended for tating and life-threatening diseases (85) . Stem cells are characterized by their potential to diftransplantation. Thus, although an attractive technology with therapeutic potential is available, the availability of ferentiate into mature cell types that may have therapeu- tic benefit in the support, repair, and regeneration of tisnew therapies, adult and embryonic stem cell research focuses on maintenance, proliferation and differentiasues damaged by disease or trauma (79) .
Cell-based therapies involve the transplantation of tion, and tissue formation in vitro. Numerous groups already work on derivation and characterization of spehealthy cells to replace damaged cells [to treat diseases such as liver disease (99), heart disease (98), diabetes cific stem cell lineages, but the underlying mechanisms are only partly understood. (55), Parkinson's disease (51), and muscular dystrophy (14) ], or the use of bioartificial organs to support paSeveral fundamental questions remain to be answered: tients until organ recovery or whole organ transplanta-
• Can we control proliferation/differentiation of selected tion [to treat diseases such as liver disease (89) and kidstem cells in vitro? ney disease (47)].
• Can we maintain the genotype/phenotype stability of To realize the full therapeutic potential of stem cells, selected stem cells in vitro? many investigators are seeking in vitro methods for
• Can specific microenvironmental conditions be used maintaining the unspecialized state of stem cells, proto control in vitro maintenance of selected stem cells? moting the proliferation of stem cells, and directing the
• Can a phenotypic stabilization of selected stem cells differentiation of stem cells to the needed specialized be achieved by 3D high-density coculture with intecells.
grated oxygenation and decentralized mass exchange? The objective of our work was to scale down the • Can, after inoculation of selected isolated stem cells, four-compartment 3D stem cell bioreactor technology tissue restructuring be achieved by the cells themplatform to study embryonic, fetal, and adult stem cells selves? in a tightly controlled environment (Fig. 2) . We cultured
• Can tissue formation by selected stem cells be infetal liver stem cells in the bioreactors. During developduced and controlled in vitro? ment, hepatic induction in mice begins as early as E9
• Can we establish in vitro a tissue density of a larger and a liver bud is recognizable at this stage (54, 109) . In number of selected stem cells without central necrosis? collaboration with the laboratory of Paul Monga, De-
• Can a reproducible proliferation/differentiation and partment of Pathology at the University of Pittsburgh, utilization of selected stem cells be achieved in vitro? we have utilized microscopically dissected embryonic
• Can specific macroenvironmental conditions, such as livers from different stages of liver development includ-3D high-density coculture with integrated oxygening E10 through E14, and performed collagenase cell ation and decentralized mass exchange, be used to dissociation. A progenitor pool was maintained over at control in vitro maintenance of human embryonic least 3 weeks, exhibiting a growing cell mass, differentistem cells in a larger cell mass? ation towards liver tissue while the early progenitors
• Does the integration of a more physiological tissue were also increasing in number. Initial bioreactor culmacroenvironment by the hollow fiber membranes tures of human fetal liver cell preparations exhibited into a growing cell mass result in a genotypic/phenocomparable results to those of mice fetal liver cells.
typic stabilization of proliferating human embryonic There are several applications for stem cell-related stem cells? research in the development of new products in medi-
• Can a compartmentalized coculture of feeder cells and cine. Further advancement of stem cell-related research human embryonic stem cells better support HESC in may evolve new therapies in transplantation medicine a growing cell mass? such as cell transplantation and extracorporeal bioreac-
• Can we maintain the stability of human embryonic tor application for temporary support of a failing organ.
stem cells in vitro, while they are proliferating as a In selected indications initial efforts are being made to larger mass? replace the actual organ transplantation with adult cell transplantation. However, stem cell transplantation may For several topics, experimental animal source or biopsied human tissue, as well as conventional petri dish be more suitable than transplantation of the fully differentiated adult derivatives, because of better retention of in vitro culture methods seem to provide appropriate tools for investigation. However, investigations focusing the ability to form junctions and communicate with host cells.
on the impact of exogenous factors could benefit from the use of purpose-built bioreactors that enable 3D high-CHALLENGES REGARDING density tissue coculture. There is a considerable need for STEM CELL RESEARCH such in vitro stem cell systems, because the stem cell-FOR LIVER SUPPORT DEVELOPMENT derived tissues must be capable of stable and long-term integration into a bioreactor or, after transplantation, into The current challenge that prevents stem cells from use in these applications is directing the full differentiaexisting physiological tissues, at least until they are replaced by the body's own tissue repair process, or pertion of their progeny in vitro. In order to further develop S96 GERLACH manently if self-repair is not possible (5). At least some ment for primary and stem cells is the understanding of modeling of cells to allow recovery from isolation injury of such studies require reproducible and controllable in vitro conditions. in vitro and to restructure functional tissue with organ functions ex vivo. Furthermore, bioreactor technology We believe that to guide tissue assembly by the cells themselves, maintenance, and proliferation/differentiaaims to contribute to further the understanding of the behavior of cells, and to control mechanisms of tissue tion of stem cells, a switch from the conventional twoor three-compartment systems towards a four-compartformation. This implies to engineer technology to create functional tissue in vitro. Several technologies have ment technology is necessary.
Our working hypothesis states that 3D cell-cell conbeen developed (Table 4) . The development of specific 3D tissue density bioretact of various stem cell populations in a perfused macroenvironment, providing decentralized mass exchange actor technology for stem cells and cocultures appears important in the context of the development of culture at physiological tissue gradients and integral oxygenation, will allow a better approximation to the in vivo models and specific cells, as well as for subsequent translation of the findings to work on animal models, situation. There, embryonic stem cells form microvascular structures and adult stem cells reside and act in such establish cell banks, and possible clinical trials. Only few data are available about theoretical considerations microvascularised tissues. A four-compartment bioreactor technology platform allows addressing the technical in the development of such bioreactors. Current bioreactor designs span a wide range of gerealization. Furthermore, we hypothesize that stem cells themselves can create their own typical microenvironometries, flow arrangements, and exchange conditions. Selected bioreactor motifs [e.g., multiaxial hollow fiber ment in such in vitro culture models, and adult stem cells benefit from parenchymal/nonparenchymal cell co- (68) and flat plate bioreactors (94)] have been modeled using simple engineering equations that relate operating culture in such systems for the creation of an organotypical microenvironment.
parameters to conditions within the local cellular environment (e.g., plasma flow rates in cell chambers, oxy-BIOREACTOR TECHNOLOGY OVERVIEW gen tension profiles, etc.) and specific biological performance measures (e.g., detoxification, albumin production, In vitro control of adult liver stem cells differentiation by mediators is studied by many groups. Of the etc.). These idealized geometries are excellent tools for investigating the impact of the microenvironment upon progenitors, the "small hepatocytes/oval cells" were described more in detail (16, 71, 72) . The effects of growth cell behavior and function; however, the extension of these designs toward clinical dimensions has been a factors, cytokines, or mediators and their role on growth/ differentiation of fetal liver stem cells, as well as estabchallenge. In contrast, the four-compartment hollow fiber-based bioreactor technology presented here has been lishing of cell lines, was also studied (108) . Hepatocyte growth factor (HGF), for example, is generally known scaled up from small analytical devices (cell mass of 0.1 g) towards clinical bioartificial liver support units (cell to stimulate hepatocytes to replicate in vitro, or oncostatin M, a multifunctional cytokine of the interleukin-6 mass of 600 g). family, has been shown to both induce maturation of THE CONCEPT OF MODULAR mice fetal hepatocytes in vitro (56, 63, 87) , and to attenu-EXTRACORPOREAL LIVER SUPPORT (MELS) ate fetal liver hematopoiesis (59) .
Several authors noted that 3D culture is an important An extracorporeal liver support system has to support or substitute the main functions of the liver, providing factor not only in accommodating an organ-like mass but also in enhancing physical cell-cell contact, accudetoxification, synthesis, and regulation. To date, developments have concentrated on either artificial detoxifimulation of extracellular matrices, and local growth factor delivery, resulting (for example) in better maintecation systems [such as albumin dialysis (96) or adsorber suspension with activated charcoal particles and nance of fetal mouse hepatocytes compared to those in monolayer cultures (53, 76) .
ion exchange resin (4,64,105)], or on biologic systems [like whole organ perfusion and bioreactors with liver The aim of advanced bioreactor technology development for mammalian tissue culture is to allow cells to cells (28) ]. For detoxification (e.g., removal of bilirubin, bile restructure functional tissue with organ functions ex vivo. Additionally, bioreactor technology developers acids, and toxins) simple, dialysis-like artificial detoxification systems have been shown to be efficient. The aim to further the understanding of the behavior of cells and the mechanisms of tissue formation. Many different complex tasks of regulation (e.g., CNS transmitter precursors) and synthesis (e.g., coagulation factors) remain bioreactor constructions have been developed and tested in vitro (Table 3) .
to be addressed by the use of human liver cells. The Modular Extracorporeal Liver Support (MELS) The general aim of bioreactor technology develop- concept combines different extracorporeal therapy units, tion of a neo-space of Dissé. The cells produce their own biomatrix; the use of fetal calf serum and additional tailored to suit the individual clinical needs of each patient (Fig. 4) . The CellModule is a specific bioreactor (animal-derived) biomatrix collagen can be avoided. A cell mass of 400-600 g enables the clinical application charged with primary human liver cells, harvested from explanted livers found to be unsuitable for transplantaof a liver lobe equivalent to a hybrid organ. The bioreactor constructions were investigated in vitro (39) therapeutic use, the bioreactors are characterized routinely concerning metabolic activity on a daily basis and The mobile trolley-mounted liver support system consists of a blood circuit with a continuous plasma sepcontamination can be excluded. In liver failure the insufficient metabolism of endogearation unit (e.g., CRRT, B. Braun, Melsungen, Germany), a high-flux dialysis filter (Fresenius Medical nous toxins has been shown to be fatal. Most of these toxins are albumin bound. In previous reports, liver asCare, Bad Homburg, Germany), and a second circuit for plasma perfusion of the bioreactor (800 ml bioreactor, sist devices based on albumin dialysis were found to eliminate these toxins (73, 93) . The DetoxModule enHybrid Organ, Berlin, Germany). The simple set-up allows the integration of any other standard renal reables albumin dialysis via a standard high-flux dialysis cartridge. Single-pass albumin dialysis (SPAD) is a simplacement therapy device. Venous access is gained by placing a double-lumen dialysis catheter into either the ple implementation of albumin dialysis using standard renal replacement therapy machines (65) : the patient's internal jugular or the femoral vein. Blood is pumped through a hollow fiber plasma filter (Plasmaselect 0.4, blood flows through a circuit with a high-flux hollow fiber hemodiafilter (Fresenius HdF 100S polysulfone Braun) at a rate of 150-250 ml/min. If necessary, a continuous infusion of heparin can be performed for anticohigh-flux hemodiafilter, Fresenius AG, Bad Homburg). The other side of this membrane is cleansed by an albuagulation in order to achieve an activated clotting time of 160-180 s (ACT, Fresenius, Oberursel, Germany). min solution in counterdirectional flow and discarded after passing the filter. One liter of a 4.5-L bag with For continuous exchange with the CellModule, the bioreactor is connected to the plasma circuit in counterdirecstandard bicarbonate-buffered dialysis solution is replaced by 1000 ml of 20% human albumin solution, resulting tional flow mode at 150-200 ml/min. The total extracorporeal volume is approximately 110 ml in the blood in 4.44% albumin solution. During therapy, the blood pump speed is adjusted to 130-180 ml/min; the dialysis circuit, and 900 ml of plasma in the bioreactor and associated circuitry.
pump speed is 600 ml/h. Thirty to 75% of all patients in ALF show renal failThe CellModule is the multicompartment bioreactor for extracorporeal liver support therapy, described above.
ure with fluid overload, electrolyte derangement, and high levels of creatinin. Therefore, the MELS concept In our actual concept, the CellModule is loaded with human liver cells, harvested from organs explanted for facilitates an integrated renal replacement therapy in terms of a continuous veno-venous hemodiafiltration via LTx but subsequently discarded due to steatosis, cirrhosis, or mechanical injury. Cells are obtained through a the high-flux hollow fiber hemodiafilter as part of the DetoxModule. A standard buffered aqueous solution is five-step collagenase liver perfusion (32). Under conditions of capillary perfusion, parenchymal and nonparenused (added after the filter, "postdilution") with a flow rate of 1000-3000 ml/h. chymal cells form tissue by spontaneous organization to cellular aggregates, immobilized to the surface of the The proposed system for extracorporeal liver support is modular and combines cell-based therapy with differcapillaries. Within these aggregates, channels are formed, representing neo-sinusoidal structures with a reformaent forms of dialysis and detoxification. One modular system for all relevant extracorporeal liver support thertor. The DialysisModule as renal replacement therapy permits regulation and detoxification. The proposed conapies facilitates handling on the intensive care unit and reduces costs for disposables, service, and technical supcept is currently under clinical investigation in a Phase I study. port. Modularity allows the clinician to adapt the extracorporeal liver support to the individual, actual needs of REFERENCES the patient suffering from liver failure.
Reduction of albumin-bound toxins or drugs, reduc-
